Sickle cell disease

A question of equity and quality

Lauren A. Smith, Suzette Olu Busola Oyeku, Charles Homer, Barry Zuckerman

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Thirty years ago, the first major federal legislation concerning sickle cell disease treatment was passed, resulting in the development of comprehensive sickle cell centers. We are now at another watershed moment in the treatment of this illness with the passage in October 2004 of the Sickle Cell Treatment Act, designed to substantially expand specialized sickle cell treatment programs. This legislation offers a remarkable opportunity to significantly improve health outcomes for individuals with sickle cell disease if it is implemented with a specific focus on the distinct but related issues of equity and quality. Despite major advances in sickle cell disease treatment that have occurred over the past 3 decades, important gaps exist both in the equity of government and private philanthropic support for research and in the uniform provision of high quality clinical care. This article assesses the current gaps in funding support and in the implementation of improvements in clinical care in order to suggest strategies for making optimal use of the opportunity that the new legislation presents to improve the health of all individuals affected by this disease.

Original languageEnglish (US)
Pages (from-to)1763-1770
Number of pages8
JournalPediatrics
Volume117
Issue number5
DOIs
StatePublished - May 2006
Externally publishedYes

Fingerprint

Sickle Cell Anemia
Legislation
Quality of Health Care
Health
Research

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Sickle cell disease : A question of equity and quality. / Smith, Lauren A.; Oyeku, Suzette Olu Busola; Homer, Charles; Zuckerman, Barry.

In: Pediatrics, Vol. 117, No. 5, 05.2006, p. 1763-1770.

Research output: Contribution to journalArticle

Smith, LA, Oyeku, SOB, Homer, C & Zuckerman, B 2006, 'Sickle cell disease: A question of equity and quality', Pediatrics, vol. 117, no. 5, pp. 1763-1770. https://doi.org/10.1542/peds.2005-1611
Smith, Lauren A. ; Oyeku, Suzette Olu Busola ; Homer, Charles ; Zuckerman, Barry. / Sickle cell disease : A question of equity and quality. In: Pediatrics. 2006 ; Vol. 117, No. 5. pp. 1763-1770.
@article{090c2e1dcb90476da1b19f8be95b5f35,
title = "Sickle cell disease: A question of equity and quality",
abstract = "Thirty years ago, the first major federal legislation concerning sickle cell disease treatment was passed, resulting in the development of comprehensive sickle cell centers. We are now at another watershed moment in the treatment of this illness with the passage in October 2004 of the Sickle Cell Treatment Act, designed to substantially expand specialized sickle cell treatment programs. This legislation offers a remarkable opportunity to significantly improve health outcomes for individuals with sickle cell disease if it is implemented with a specific focus on the distinct but related issues of equity and quality. Despite major advances in sickle cell disease treatment that have occurred over the past 3 decades, important gaps exist both in the equity of government and private philanthropic support for research and in the uniform provision of high quality clinical care. This article assesses the current gaps in funding support and in the implementation of improvements in clinical care in order to suggest strategies for making optimal use of the opportunity that the new legislation presents to improve the health of all individuals affected by this disease.",
author = "Smith, {Lauren A.} and Oyeku, {Suzette Olu Busola} and Charles Homer and Barry Zuckerman",
year = "2006",
month = "5",
doi = "10.1542/peds.2005-1611",
language = "English (US)",
volume = "117",
pages = "1763--1770",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "5",

}

TY - JOUR

T1 - Sickle cell disease

T2 - A question of equity and quality

AU - Smith, Lauren A.

AU - Oyeku, Suzette Olu Busola

AU - Homer, Charles

AU - Zuckerman, Barry

PY - 2006/5

Y1 - 2006/5

N2 - Thirty years ago, the first major federal legislation concerning sickle cell disease treatment was passed, resulting in the development of comprehensive sickle cell centers. We are now at another watershed moment in the treatment of this illness with the passage in October 2004 of the Sickle Cell Treatment Act, designed to substantially expand specialized sickle cell treatment programs. This legislation offers a remarkable opportunity to significantly improve health outcomes for individuals with sickle cell disease if it is implemented with a specific focus on the distinct but related issues of equity and quality. Despite major advances in sickle cell disease treatment that have occurred over the past 3 decades, important gaps exist both in the equity of government and private philanthropic support for research and in the uniform provision of high quality clinical care. This article assesses the current gaps in funding support and in the implementation of improvements in clinical care in order to suggest strategies for making optimal use of the opportunity that the new legislation presents to improve the health of all individuals affected by this disease.

AB - Thirty years ago, the first major federal legislation concerning sickle cell disease treatment was passed, resulting in the development of comprehensive sickle cell centers. We are now at another watershed moment in the treatment of this illness with the passage in October 2004 of the Sickle Cell Treatment Act, designed to substantially expand specialized sickle cell treatment programs. This legislation offers a remarkable opportunity to significantly improve health outcomes for individuals with sickle cell disease if it is implemented with a specific focus on the distinct but related issues of equity and quality. Despite major advances in sickle cell disease treatment that have occurred over the past 3 decades, important gaps exist both in the equity of government and private philanthropic support for research and in the uniform provision of high quality clinical care. This article assesses the current gaps in funding support and in the implementation of improvements in clinical care in order to suggest strategies for making optimal use of the opportunity that the new legislation presents to improve the health of all individuals affected by this disease.

UR - http://www.scopus.com/inward/record.url?scp=33646850197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646850197&partnerID=8YFLogxK

U2 - 10.1542/peds.2005-1611

DO - 10.1542/peds.2005-1611

M3 - Article

VL - 117

SP - 1763

EP - 1770

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 5

ER -